St. Louis, Missouri – June 3, 2008 – Partek Incorporated announced today that it has licensed Partek® Genomics SuiteTM (Partek GS) software to the Australian Neuromuscular Research Institute (ANRI).

Researchers at ANRI will use Partek GS to analyze exon and alternative splicing data. Areas of research at ANRI include brain function, gene therapy, motor control, Parkinson’s Disease, and stroke. ANRI is located in Western Australia.

Partek GS can analyze expression, digital gene expression, ChIP-seq/ChIP-chip, exon/alternative splicing, SNP genotyping, and next generation sequencing data. In addition, data can be seamlessly imported from a variety of file formats.

Partek Incorporated is a leading provider of statistical analysis and interactive data visualization software for the scientific research community. Partek software enables researchers to quickly identify and quantify patterns in data, including data resulting from genomic and proteomic studies, high-throughput screening campaigns, and computer aided drug design.

Press Release: 
Story Type: